Cargando…

Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019

Background: Coronavirus disease 2019 (COVID-19) is a novel disease associated with a cytokine-mediated, severe, acute respiratory syndrome. Tocilizumab and lenzilumab are recombinant monoclonal antibodies against IL-6 and granulocyte macrophage colony-stimulating factor, respectively, and have been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melody, Megan, Nelson, Jared, Hastings, Jacquelyn, Propst, Joshua, Smerina, Michael, Mendez, Julio, Guru, Pramod
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319491/ https://www.ncbi.nlm.nih.gov/pubmed/32546029 http://dx.doi.org/10.2217/imt-2020-0136

Ejemplares similares

Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Aroldi, Andrea, et al.
Publicado: (2021)

In Reply — Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Temesgen, Zelalem, et al.
Publicado: (2021)

1134. Lenzilumab Treatment in COVID-19 Pneumonia Reduces Circulating Cytokines and Markers of Systemic Inflammation
por: Chappell, Dale, et al.
Publicado: (2022)

Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019
por: Ozkan, Feyza, et al.
Publicado: (2022)

Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?
por: Klopfenstein, Timothée, et al.
Publicado: (2021)

GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study
por: Temesgen, Zelalem, et al.
Publicado: (2020)

Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019
por: Mombrun, Martin, et al.
Publicado: (2021)

P737: LENZILUMAB AND AZACITIDINE IMPROVE HEMATOLOGIC ALTERATIONS OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE PREACH-M TRIAL
por: Ross, David, et al.
Publicado: (2023)

Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients
por: Sirimaturos, Michael, et al.
Publicado: (2020)

Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review
por: Jorgensen, Sarah C.J., et al.
Publicado: (2022)

Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports
por: Abdullah, Shazia, et al.
Publicado: (2021)

Effect of Tocilizumab Treatment on Patients with Coronavirus Disease 2019 and Bacteremia: A Retrospective Cohort Study
por: Kuwahara, Masaatsu, et al.
Publicado: (2022)

Effect of tocilizumab treatment in mildly-obese patients with coronavirus disease 2019: a case series
por: Abe, Takashi, et al.
Publicado: (2022)

Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab
por: Morrison, Austin R., et al.
Publicado: (2020)

A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019
por: Lewis, Tyler C., et al.
Publicado: (2020)

Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab
por: Hartog, Nicholas L., et al.
Publicado: (2021)

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
por: Price, Christina C., et al.
Publicado: (2020)

Tocilizumab in the treatment of coronavirus disease 2019 pneumonia: real-world data from a case series
por: Cui, Ran, et al.
Publicado: (2021)

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
por: Temesgen, Zelalem, et al.
Publicado: (2022)

Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England
por: Kilcoyne, Adrian, et al.
Publicado: (2022)

Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19)
por: Chen, Chong-xiang, et al.
Publicado: (2021)

Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab
por: Tabarsi, Payam, et al.
Publicado: (2021)

Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality
por: Sinha, Pranay, et al.
Publicado: (2021)

Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
por: Rajendram, Prabalini, et al.
Publicado: (2021)

Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
por: Zhang, Shengyu, et al.
Publicado: (2020)

C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL
por: TEMESGEN, ZELALEM, et al.
Publicado: (2021)

Therapeutic Effect of Tocilizumab on Inhibiting Cytokine Release Syndrome in Severe Coronavirus Disease 2019 Patients
por: Xu, Lengnan, et al.
Publicado: (2022)

Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019
por: Gao, Qian, et al.
Publicado: (2022)

Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19)
por: Lohse, Anne, et al.
Publicado: (2020)

C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial
por: Temesgen, Zelalem, et al.
Publicado: (2023)

Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
por: Liu, Danfei, et al.
Publicado: (2020)

Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial*
por: Tom, Jennifer, et al.
Publicado: (2021)

Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction
por: Melody, Megan, et al.
Publicado: (2020)

Diagnostic and treatment dilemma during the coronavirus disease 2019 pandemic: a primary pulmonary lymphoma presenting as a cavitary mass in a patient with coronavirus disease 2019: a case report
por: Wong, Fatima, et al.
Publicado: (2023)

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
por: Veiga, Viviane C, et al.
Publicado: (2021)

Tocilizumab: Invasive pulmonary aspergillosis following off-label use of tocilizumab for severe acute respiratory coronavirus-2 infection: case report
Publicado: (2021)

LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
por: Temesgen, Zelalem, et al.
Publicado: (2021)

40. Lenzilumab Efficacy and Safety in Newly Hospitalized COVID-19 Subjects: Results From a Phase 3 Randomized Double-Blind Placebo-Controlled Trial
por: Temesgem, Zelalem, et al.
Publicado: (2021)

Famotidine and Mortality in Coronavirus Disease 2019
por: Sethia, Rahul, et al.
Publicado: (2021)

Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach
por: Sarma, Phulen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fjfnq7iub6lk1r8sqdddfo6ccb